Bibliography
- Epstein M, Campese VM. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors on renal function. Am J Kidney Dis 2005;45:2-14
- Rysz J, Banach M, Ciałkowska-Rysz A, et al. Blood serum levels of IL-2, IL-6, IL-8, TNF-α and IL-1β in patients on maintenance hemodialysis. Cell Mol Immunol 2006;3:151-4
- Jacobson SH, Egberg N, Hylander B, Lundahl J. Correlation between soluble markers of endothelial dysfunction in patients with renal failure. Am J Nephrol 2002;22:42-7
- Efstratiadis G, Tziomalos K, Mikhailidis DP, et al. Atherogenesis in renal patients: a model of vascular disease? Curr Vasc Pharmacol 2008;6:93-107
- Rysz J, Majewska E, Stolarek RA, et al. Increased levels of soluble TNF-α receptors and cellular adhesion molecules in patients undergoing bioincompatible hemodialysis. Am J Nephrol 2006;26:437-44
- Piechota M, Banach M, Jacoń A, Rysz J. Natriuretic peptides in cardiovascular diseases. Cell Mol Biol Lett 2008;13:155-81
- Papagianni A, Kalovoulos M, Kirmizis D, et al. Carotid atherosclerosis is associated with inflammation and endothelial cell adhesion molecules in chronic haemodialysis patients. Nephrol Dial Transplant 2003;18:113-9
- Frieling JT, van Hamersvelt HW, Wijdenes J, et al. Circulating concentrations of soluble interleukin 6 receptors gp80 and gp130 in chronic renal failure and effects of renal replacement therapy. Am J Nephrol 1999;19:571-5
- Papagianni A, Kokolina E, Kalovoulos M, et al. Carotid atherosclerosis is associated with inflammation, malnutrition and intercellular adhesion molecule-1 in patients on continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 2004;19:258-63
- Ganotakis ES, Vrentzos GE, Gazi IF, et al. Fibrinogen, lipoprotein (a), albumin and bilirubin (F-L-A-B) levels and cardiovascular risk calculated using the Framingham equation. In Vivo 2007;21:685-94
- Krijgsman B, Papadakis JA, Ganotakis ES, et al. The effect of peripheral vascular disease on the serum levels of natural anti-oxidants: bilirubin and albumin. Int Angiol 2002;21:44-52
- Shaper AG, Wannamethee SG, Whincup PH. Serum albumin and risk of stroke, coronary heart disease, and mortality: the role of cigarette smoking. J Clin Epidemiol 2004;57:195-202
- Phillips A, Shaper AG, Whincup PH. Association between serum albumin and mortality from cardiovascular disease, cancer, and other causes. Lancet 1989;2:1434-6
- Mikhailidis DP, Ganotakis ES. Plasma albumin and platelet function: relevance to atherogenesis and thrombosis. Platelets 1996;7:125-37
- Ashman N, Macey MG, Fan SL, et al. Increased platelet-monocyte aggregates and cardiovascular disease in end-stage renal failure patients. Nephrol Dial Transplant 2003;18:2088-96
- Inoue H, Saito I, Nakazawa R, et al. Expression of inflammatory cytokines and adhesion molecules in haemodialysis-associated amyloidosis. Nephrol Dial Transplant 1995;10:2077-82
- Peppa M, Uribarri J, Cai W, et al. Glycoxidation and inflammation in renal failure patients. Am J Kidney Dis 2004;43:690-5
- Cominacini L, Garbin U, Pasini AF, et al. Antioxidants inhibit the expression of intercellular cell adhesion molecule-1 and vascular cell adhesion molecule-1 induced by oxidized LDL on human umbilical vein endothelial cells. Free Radic Biol Med 1997;22:117-27
- Wang CY, Liao JK. Current advances in statin treatment: from molecular mechanisms to clinical practice. Arch Med Sci 2007;3:S91-6
- Li C, Sun BK, Lim SW, et al. Combined effects of losartan and pravastatin on interstitial inflammation and fibrosis in chronic cyclosporine-induced nephropathy. Transplantation 2005;79:1522-9
- Kovesdy CP, Kalantar-Zadeh K. Lipids in aging and chronic illness: impact on survival. Arch Med Sci 2007;3:S74-80
- Habib AN, Baird BC, Leypoldt JK, et al. The association of lipid levels with mortality in patients on chronic peritoneal dialysis. Nephrol Dial Transplant 2006;21:2881-92
- Iseki K, Yamazato M, Tozawa M, Takishita S. Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int 2002;61:1887-93
- Liu Y, Coresh J, Eustace JA, et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 2004;291:451-9
- Wan RK, Mark PB, Jardine AG. The cholesterol paradox is flawed; cholesterol must be lowered in dialysis patients. Semin Dial 2007;20:504-9
- Baigent C, Landray M, Warren M. Statin therapy in kidney disease populations: potential benefits beyond lipid lowering and the need for clinical trials. Curr Opin Nephrol Hypertens 2004;13:601-5
- Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353:238-48
- Kovesdy CP, Anderson JE, Kalantar-Zadeh K. Inverse association between lipid levels and mortality in men with chronic kidney disease who are not yet on dialysis: effects of case mix and the malnutrition-inflammation-cachexia syndrome. J Am Soc Nephrol 2007;18:304-11
- Kovesdy CP, Anderson JE, Kalantar-Zadeh K. Paradoxical association between body mass index and mortality in men with CKD not yet on dialysis. Am J Kidney Dis 2007;49:581-91
- Qi W, Poronnik P, Young B, et al. Human cortical fibroblast responses to high glucose and hypoxia. Nephron Physiol 2004;4:121-9
- Rysz J, Banach M, Stolarek RA, et al. Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy. J Nephrol 2007;20:444-52
- Akahane T, Akahane M, Shah A, Thorgeirsson UP. TIMP-1 stimulates proliferation of human aortic smooth muscle cells and Ras effector pathways. Biochem Biophys Res Commun 2004;324:440-5
- Kowalski J, Banach M, Barylski M, et al. Neutrophil superoxide anion generation during atorvastatin and fluvastatin therapy used in coronary heart disease primary prevention. J Cardiovasc Pharmacol 2006;48:143-7
- Zeisberg M, Maeshima Y, Mosterman B, Kalluri R. Renal fibrosis. Extracellular matrix microenvironment regulates migratory behavior of activated tubular epithelial cells. Am J Pathol 2002;160:2001-8
- Cheng S, Lovett DH. Gelatinase A (MMP-2) is necessary and sufficient for renal tubular cell epithelial–mesenchymal transformation. Am J Pathol 2003;162:1937-49
- McLennan SV, Fisher E, Martell SY, et al. Effects of glucose on matrix metalloproteinase and plasmin activities in mesangial cells: possible role in diabetic nephropathy. Kidney Int Suppl 2000;77:S81-7
- Ebihara I, Nakamura T, Shimada N, Koide H. Increased plasma metalloproteinase-9 concentrations precede development of microalbuminuria in non-insulin-dependent diabetes mellitus. Am J Kidney Dis 1998;32:544-50
- Song Y, Li C, Cai L. Fluvastatin prevents nephropathy likely through suppression of connective tissue growth factor-mediated extracellular matrix accumulation. Exp Mol Pathol 2004;76:66-75
- Chen HC, Guh JY, Tan MC, et al. Pravastatin suppress superoxide and fibronectin production of glomerular mesangial cells induced by oxidized-LDL and high glucose. Atherosclerosis 2002;160:141-6
- Yokota T, Utsunomiya K, Murakawa Y, et al. Mechanism of preventive effect of HMG-CoA reductase inhibitor on diabetic nephropathy. Kidney Int 1999;71:S178-81
- Danesh FR, Sadeghi MM, Amro N, et al. 3-hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTAase/p21 signaling pathway: implications for diabetic nephropathy. Proc Natl Acad Sci USA 2002;99:8301-5
- Heusinger-Ribeiro J, Fischer B, Goppelt-Struebe M. Differential effects of simvastatin on mesangial cells. Kidney Int 2004;66:187-95
- Rysz J, Blaszczak R, Banach M, et al. Evaluation of chosen parameters of antioxidative system in patients with type 2 diabetes in different periods of metabolic compensation. Arch Immunol Ther Exp 2007;55:335-40
- Jenkins AL, Lyons TJ, Zheng D, et al. Lipoproteins in the DCCT/EDIC cohort: association with diabetic nephropathy. Kidney Int 2003;64:817-28
- Yoshino G, Hirano T, Kazumi T. Atherogenic lipoproteins and diabetes mellitus. J Diabetes Complications 2002;16:29-34
- Kronenberg F, Lingenhel A, Lhotta K, et al. Lipoprotein (a)- and low-density lipoprotein-derived cholesterol in nephrotic syndrome: impact on lipid-lowering therapy? Kidney Int 2004;66:348-54
- Eto M, Saito M, Okada M, et al. Apolipoprotein E genetic polymorphism, remnant lipoproteins, and nephropathy in type 2 diabetic patients. Am J Kidney Dis 2002;40:243-51
- Soedamah-Muthu SS, Colhoun HM, Taskinen MR, et al. Differences in HDL-cholesterol:apoA-I + apoA-II ratio and apoE phenotype with albuminuric status in type 1 diabetic patients. Diabetologia 2000;43:1353-9
- Hsieh MC, Lin SR, Yang YC, et al. Increased frequency of apolipoprotein E2 allele in type 2 diabetic patients with nephropathy in Taiwan. J Nephrol 2002;15:368-73
- Chen HC, Tan MS, Guh JY, et al. Native and oxidative LDL enhance superoxide production from diabetic rat glomeruli. Kidney Blood Press Res 2000;23:133-7
- Chen HC, Guh JY, Shin SJ, et al. Reactive oxygen species enhances endothelin-1 production of diabetic rat glomeruli in vitro and in vivo. J Lab Clin Med 2000;135:309-15
- Dominguez JH, Tang N, Xu W, et al. Studies of renal injury. III: lipid-induced nephropathy in type II diabetes. Kidney Int 2000;57:92-104
- O'Donell MP, Kasiske BL, Kim Y, et al. Lovastatin inhibits proliferation of rat mesangial cells. J Clin Invest 1993;91:83-7
- Corsini A, Mazzotti M, Raiteri M, et al. Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase. Atherosclerosis 1993;101:117-25
- Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425-9
- Sakai M, Kobori S, Matsumura T, et al. HMG-CoA reductase suppress macrophage growth induced by oxidized low density lipoprotein. Atherosclerosis 1997;133:51-9
- Weiss RH, Ramirez A, Joo A. Short-term pravastatin mediates growth inhibition and apoptosis, independently of Ras, via the signaling proteins p27Kip1 and P13 kinase. J Am Soc Nephrol 1999;10:1880-90
- Sukhija R, Bursac Z, Kakar P, et al. Effect of statins on the development of renal dysfunction. Am J Cardiol 2008;101:975-9
- Farbakhsh K, Kasiske BL. Dyslipidemias in patients who have chronic kidney disease. Med Clin North Am 2005;89:689-99
- Wanner C, Krne V, Marz W, et al. Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D Study): demographic and baseline characteristics. Kidney Blood Press Res 2004;27:259-66
- Fellström B, Abedini S, Holdaas H, et al. No detrimental effect on renal function during long-term use of fluvastatin in renal transplant recipients in the Assessment of Lescol in Renal Transplantation (ALERT) study. Clin Transplant 2006;20:732-9
- Krane V, Wanner C. Statins and aspirin in chronic renal disease: what does the UK-HARP-I trial tell us? Am J Kidney Dis 2005;45:607-9
- National Kidney Foundation K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Transplant 2004;4(Suppl 7):13-53
- Kasiske BL, O'Donnell MP, Cleary MP, et al. Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int 1988;33:667-72
- Kasiske BL, O'Donnell MP, Garvis WJ, et al. Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure. Circ Res 1988;62:367-74
- Harris KPG, Pukerson ML, Yates J, et al. Lovastatin ameliorates the development of glomerulosclerosis and uremia in experimental nephrotic syndrome. Am J Kidney Dis 1990;15:16-23
- Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004;57:728-34
- Tonelli M, Isles C, Craven T, et al. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation 2005;112:171-8
- Tonelli M, Sacks F, Pfeffer M, et al. Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int 2005;68:237-45
- Lemos PA, Serruys PW, de Feyter P, et al. Long-term fluvastatin reduces the hazardous effect of renal impairment on four-year atherosclerotic outcomes (a LIPS substudy). Am J Cardiol 2005;95:445-51
- Ezekowitz J, McAlister FA, Humphries KH, et al. The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. J Am Coll Cardiol 2004;44:1587-92
- Shepherd J, Kastelein JJ, Bittner V, et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol 2008;51:1448-54
- Shepherd J, Kastelein JJ, Bittner V, et al. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol 2007;2:1131-9
- Baigent C, Landray M, Warren M. Statin therapy in kidney disease populations: potential benefits beyond lipid lowering and the need for clinical trials. Curr Opin Nephrol Hypertens 2004;13:601-5
- Zhou MS, Schuman IH, Jaimes EA, et al. Renoprotection by statins is linked to a decrease in renal oxidative stress, TGF-β, and fibronectin with concomitant increase in nitric oxide bioavailability. Am J Physiol Renal Physiol 2008;295:F53-9
- Ford I, Bezlyak V, Stott DJ, et al. Reduced glomerular filtration rate and its association with clinical outcome in older patients at risk of vascular events: secondary analysis. PLoS Med 2009;6:e16. Published online 20 January 2009, doi:10.1371/journal.pmed.1000016
- Strippoli GF, Navaneethan SD, Johnson DW, et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ 2008;336:645-51
- Weiner DE, Sarnak MJ. Managing dyslipidemia in chronic kidney disease. J Gen Intern Med 2004;19:1045-52
- Banach M, Mikhailidis DP, Ugurlucan M, et al. The significance of statin use in patients subjected to surgical coronary revascularization. Arch Med Sci 2007;3:S126-32
- Banach M, Goch JH, Ugurlucan M, et al. Statins in the prevention of postoperative atrial fibrillation. Is there really no effect? Am Heart J 2008;155:e53. Published online 23 April 2008, doi:10.1016/j.ahj.2008.03.008
- Tabata M, Khalpey Z, Pirundini PA, et al. Renoprotective effect of preoperative statins in coronary artery bypass grafting. Am J Cardiol 2007;100:442-4
- Banach M, Drozdz J, Okonski P, Rysz J. Immunological aspects of the statins' function in patients with heart failure: a report from the Annual Conference of ESC – Heart Failure 2005. Cell Mol Immunol 2005;2:433-7
- Sharobeem KM, Madden BP, Millner R, et al. Acute renal failure after cardiopulmonary bypass: a possible association with drugs of the fibrate group. J Cardiovasc Pharmacol Ther 2000;5:33-9
- Paraskevas KI, Tzovaras AA, Briana DD, Mikhailidis DP. Emerging indications for statins: a pluripotent family of agents with several potential applications. Curr Pharm Des 2007;13:3622-36
- Aydin U, Ugurlucan M, Gungor F, et al. Effects of atorvastatin on vascular intimal hyperplasia: an experimental rodent model. Angiology 2009; [Epub ahead of print 15 September 2008, doi:10.1177/0003319708321102]
- Athyros VG, Elisaf M, Papageorgiou AA, et al. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis 2004;43:589-99
- Szadkowska I, Stanczyk A, Aronow WS, et al. Statin therapy in the elderly: a review. Arch Gerontol Geriatr 2009; [Epub ahead of print 13 February 2009, doi:10.1016/j.archger.2008.12.012]